XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.3
FINANCIAL INSTRUMENTS - Narrative (Details) - USD ($)
$ in Thousands, shares in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 20, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Financial Instruments [Line Items]              
Issuance of common stock in acquisition     $ 76,642   $ 76,642    
Shares issuable following milestone achievement     84,761   84,761    
Contingent consideration liability, current $ 96,193   96,193   96,193   $ 172,094
Investment income, net     9,200 $ 2,800 25,000 $ 4,300  
Additional Paid-in Capital              
Financial Instruments [Line Items]              
Issuance of common stock in acquisition     76,636   76,636    
Shares issuable following milestone achievement     84,761   84,761    
Omniome, Inc              
Financial Instruments [Line Items]              
Cash payments   $ 100,900          
Issuance of common stock in acquisition (in shares)   9.0          
Issuance of common stock in acquisition   $ 95,900          
Average trading period   20 days          
Trading period prior to achievement of milestone   2 days          
Milestone revenue     5,100   5,100    
Contingent consideration liability, current 96,200   $ 96,200   $ 96,200    
Omniome, Inc | Additional Paid-in Capital              
Financial Instruments [Line Items]              
Shares issuable following milestone achievement $ 84,800            
Omniome, Inc | Common Stock              
Financial Instruments [Line Items]              
Issuance of common stock in acquisition   $ 100,000          
Omniome, Inc | Employee Stock Option              
Financial Instruments [Line Items]              
Issuance of common stock in acquisition   $ 4,100